Market Access Strategies for the Global Healthcare Environment mktxs linkedin 1-908-864-4090

Emerging Markets Access Environment Across Multiple Therapeutic Areas (TAs): Clinical and Economic Evidence Development


Client wanted to gain a deeper understanding of the Emerging Market Landscape for 5 Key TAs to inform internal stakeholder strategy and education to include:

  • Stakeholder mapping
  • Clinical/economic evidence requirements
  • Roadmap to optimize pricing and reimbursement (P&R) outcomes

Emerging Markets – Price and Access Assessment


A medium sized biotech company with no local presence in key emerging markets wanted to forecast price by understanding:

  • Key price drivers including reference countries, generic availability, level of specialization required by market type (self pay, public reimbursement, mixed markets)
  • Impact of supply chain on drug pricing (ex-factory, public, private and pharmacy selling price) and drivers for differences within and across countries
  • Differences in price drivers versus US and EU 5 markets

Risk Sharing Agreements (RSA) Landscape to Enhance Access in G-20 Markets


Client wanted to explore potential to enter into RSAs to gain early market access in light of heavy competition

  • High price product in scope offers only incremental benefit over competition